Nobuyuki Yamamoto

10PUBLICATIONS
87CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Mar 30, 2026
Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.

Toshiaki Takakura, Ryota Shibaki, Atsushi Washioka

|Jan 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

Glenwood D Goss, Gail E Darling, Virginie Westeel

|Mar 31, 2025
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata

|Sep 01, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.

Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi

|Jun 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).

Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori

Pageof 2

Frequent Collaborators

4 joint publications

Kazuhiko Nakagawa

3 joint publications

Hiroaki Akamatsu

3 joint publications

Tetsuya Mitsudomi

3 joint publications

Shunichi Sugawara